Continuing this discussion, we broaden the lens to the developing litigation environment and additional regulatory scrutiny that can affect manufacturers, pharmacies, telehealth providers, and other stakeholders across the GLP1 ecosystem
Challenges and Limitations Despite their benefits, dual agonists may not address all metabolic abnormalities, particularly in patients with complex pathophysiology involving multiple dysregulated pathways
Understanding your peptide pathway genetics allows PlexusDx providers to select the most effective medication (semaglutide injection, oral semaglutide, tirzepatide, or combination therapy) and anticipate your response timeline
The metabolic improvements from Retatrutide reduce cardiovascular disease risk by an estimated 25-30% based on established risk calculators
Statements Author contributions AH: Conceptualization, Writing original draft, Writing review & editing